Encore Medical Research - Weston

The trials here

What the 12 trials at this site are about, from their registry records.

Conditions

• Type 2 diabetes8 trials
• Obesity3 trials
• Atopic dermatitis (eczema)1 trial
• Bipolar disorder1 trial
• Chronic kidney disease1 trial
• Diabetic neuropathy1 trial
• Rheumatoid arthritis1 trial

Phase

• Phase 37 trials
• Phase 25 trials

Status

• Completed6 trials
• Active, not recruiting3 trials
• Recruiting2 trials
• Not yet recruiting1 trial

Lead sponsor

• Eli Lilly and Company10 trials
• Boehringer Ingelheim1 trial
• Hangzhou Yirui Pharmaceutical Technology Co., Ltd1 trial

Running trials

• Recruiting

  A Study of EloraTZP in Adult Participants With Obesity or Overweight and Type 2 Diabetes

  NCT07881458· Phase 3· Eli Lilly and Company· Source

  Contact: Sandro Bacchelli (principal investigator)

• Recruiting

  A Study to Test Whether Survodutide Helps People With Type 2 Diabetes Control Their Blood Sugar

  NCT07754461· Phase 3· Boehringer Ingelheim· Source

  Contact: Boehringer Ingelheim

• Active, not recruiting

  A Study of Retatrutide (LY3437943) in Participants Without Type 2 Diabetes Who Have Obesity or Overweight

  NCT07357415· Phase 3· Eli Lilly and Company· Source

• Recruiting

  A Study of Brenipatide in Adult Participants With Bipolar Disorder (RENEW-Bipolar-1)

  NCT07286175· Phase 2· Eli Lilly and Company· Source

  Contact: Luis Marchany Alfonso (principal investigator)

• Active, not recruiting

  A Study of LY3938577 in Participants With Type 2 Diabetes Previously Treated With Basal Insulin

  NCT07215312· Phase 2· Eli Lilly and Company· Source

• Active, not recruiting

  Effect of Retatrutide Compared With Placebo in Participants With Type 2 Diabetes and Moderate or Severe Renal Impairment, With Inadequate Glycemic Control on Basal Insulin, With or Without Metformin and/or SGLT2 Inhibitor (TRANSCEND-T2D-3)

  NCT06297603· Phase 3· Eli Lilly and Company· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Type 2 diabetes2 recruiting
• Bipolar disorder1 recruiting
• Obesity1 recruiting

Closed trials

• Completed

  Effects of LY3848575 Versus Placebo in Participants With Painful Distal Sensory Polyneuropathy

  NCT06568042· Phase 2· Eli Lilly and Company· Source

• Completed

  Topical YR001 Ointment in Adult With Mild to Moderate Atopic Dermatitis

  NCT06309355· Phase 2· Hangzhou Yirui Pharmaceutical Technology Co., Ltd· Source

• Completed

  A Study of Orforglipron (LY3502970) in Participants With Type 2 Diabetes and Inadequate Glycemic Control With Insulin Glargine, With or Without Metformin and/or SGLT-2 Inhibitor

  NCT06109311· Phase 3· Eli Lilly and Company· Source

• Completed

  An Adaptive Phase 2a/2b Study of LY3871801 in Adult Participants With Rheumatoid Arthritis

  NCT05848258· Phase 2· Eli Lilly and Company· Source

• Completed

  A Study of Daily Oral Orforglipron (LY3502970) Compared With Insulin Glargine in Participants With Type 2 Diabetes and Obesity or Overweight at Increased Cardiovascular Risk

  NCT05803421· Phase 3· Eli Lilly and Company· Source

• Completed

  A Study of Insulin Efsitora Alfa (LY3209590) as a Weekly Basal Insulin Compared to Insulin Glargine in Adult Participants With Type 2 Diabetes on Multiple Daily Injections

  NCT05462756· Phase 3· Eli Lilly and Company· Source